☰

Kelsie A. Mozzoni - Publications

Affiliations: 
Cognition Therapeutics 
Area:
Alzheimer's Disease and other Neurodegenerative Diseases
Tree Info Grants Similar researchers PubMed Report error

6 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Limegrover CS, LeVine H, Izzo NJ, Yurko R, Mozzoni K, Rehak C, Sadlek K, Safferstein H, Catalano SM. Alzheimer's Protection Effect of A673T Mutation May Be Driven by Lower Aβ Oligomer Binding Affinity. Journal of Neurochemistry. PMID 33025581 DOI: 10.1111/jnc.15212  0.651
2019 Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, Guttendorf R, Higgin M, Pribyl J, Mozzoni K, Safferstein H, Catalano SM. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 5: 20-26. PMID 30723776 DOI: 10.1016/J.Trci.2018.11.001  0.644
2019 Schneider LS, Caggiano AO, Grundman M, DeKosky S, Morgan R, Mozzoni K, Izzo NJ, Safferstein H, Catalano S. CLINICAL BIOMARKER EVIDENCE FOR TARGET ENGAGEMENT, REDUCTION OF SYNAPTIC DAMAGE AND DISEASE MODIFICATION IN ALZHEIMER’S PATIENTS TREATED WITH CT1812 Alzheimer's & Dementia. 15: P1603-P1604. DOI: 10.1016/J.Jalz.2019.09.072  0.384
2017 Catalano S, Grundman M, Schneider LS, DeKosky S, Morgan R, Guttendorf R, Higgin M, Pribyl J, Mozzoni K, Izzo NJ, Safferstein H. A PHASE 1 SAFETY TRIAL OF THE Aβ OLIGOMER RECEPTOR ANTAGONIST CT1812 Alzheimer's & Dementia. 13: P1570. DOI: 10.1016/J.Jalz.2017.07.730  0.461
2014 Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, Rehak C, Yurko R, Look G, Rishton G, Safferstein H, Cruchaga C, Goate A, Cahill MA, Arancio O, et al. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. Plos One. 9: e111899. PMID 25390692 DOI: 10.1371/Journal.Pone.0111899  0.677
2014 Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, et al. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. Plos One. 9: e111898. PMID 25390368 DOI: 10.1371/Journal.Pone.0111898  0.674
Show low-probability matches.